Your browser doesn't support javascript.
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.
Palandri, Francesca; Elli, Elena M; Auteri, Giuseppe; Bonifacio, Massimiliano; Benevolo, Giulia; Heidel, Florian H; Paglia, Simona; Trawinska, Malgorzata M; Bosi, Costanza; Rossi, Elena; Tiribelli, Mario; Tieghi, Alessia; Iurlo, Alessandra; Polverelli, Nicola; Caocci, Giovanni; Binotto, Gianni; Cavazzini, Francesco; Beggiato, Eloise; Cilloni, Daniela; Tatarelli, Caterina; Mendicino, Francesco; Miglino, Maurizio; Bocchia, Monica; Crugnola, Monica; Mazzoni, Camilla; Romagnoli, Andrea D; Rindone, Giovanni; Ceglie, Sara; D'Addio, Alessandra; Santoni, Eleonora; Cattaneo, Daniele; Bartoletti, Daniela; Lemoli, Roberto M; Krampera, Mauro; Cuneo, Antonio; Semenzato, Gianpietro C; Latagliata, Roberto; Abruzzese, Elisabetta; Vianelli, Nicola; Cavo, Michele; Andriani, Alessandro; De Stefano, Valerio; Palumbo, Giuseppe A; Breccia, Massimo.
  • Palandri F; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. francesca.palandri@unibo.it.
  • Elli EM; Hematology Division, San Gerardo Hospital, ASST Monza, Monza, Italy.
  • Auteri G; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
  • Bonifacio M; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
  • Benevolo G; Section of Hematology, Department of Medicine, University of Verona, Verona, Italy.
  • Heidel FH; Hematology U, Department of Oncology, Città della Salute e della Scienza, Turin, Italy.
  • Paglia S; Innere Medicine C, Universitätsmedizin Greifswald, Greifswald, Germany.
  • Trawinska MM; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
  • Bosi C; Hematology, S.Eugenio Hospital, Tor Vergata University, ASL Roma2, Rome, Italy.
  • Rossi E; Division of Hematology, AUSL di Piacenza, Piacenza, Italy.
  • Tiribelli M; Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University School of Medicine, Rome, Italy.
  • Tieghi A; Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Iurlo A; Division of Hematology and BMT, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.
  • Polverelli N; Department of Hematology, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Caocci G; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Binotto G; Unit of Blood Diseases and Stem Cell Transplantation, ASST Spedali Civili di Brescia, Brescia, Italy.
  • Cavazzini F; Hematology Unit, Businco Hospital, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
  • Beggiato E; Unit of Hematology and Clinical Immunology, University of Padova, Padova, Italy.
  • Cilloni D; Division of Hematology, University of Ferrara, Ferrara, Italy.
  • Tatarelli C; Hematology U, Department of Oncology, Città della Salute e della Scienza, Turin, Italy.
  • Mendicino F; Haematology Division, Department of Clinical and Biological Sciences, Ospedale San Luigi di Orbassano, University of Turin, Orbassano, Italy.
  • Miglino M; Hematology, S.Andrea Hospital, Rome, Italy.
  • Bocchia M; Unit of Hematology, Hospital of Cosenza, Cosenza, Italy.
  • Crugnola M; IRCCS Policlinico San Martino, Genova, Italy.
  • Mazzoni C; Dipartimento di Medicina interna e Specialità mediche, Università di Genova, Genova, Italy.
  • Romagnoli AD; Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy.
  • Rindone G; Division of Hematology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
  • Ceglie S; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
  • D'Addio A; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
  • Santoni E; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
  • Cattaneo D; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
  • Bartoletti D; Hematology Division, San Gerardo Hospital, ASST Monza, Monza, Italy.
  • Lemoli RM; Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University School of Medicine, Rome, Italy.
  • Krampera M; Division of Hematology, Onco-hematologic Department, AUSL della Romagna, Ravenna, Italy.
  • Cuneo A; Section of Hematology, Department of Medicine, University of Verona, Verona, Italy.
  • Semenzato GC; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Latagliata R; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
  • Abruzzese E; IRCCS Policlinico San Martino, Genova, Italy.
  • Vianelli N; Dipartimento di Medicina interna e Specialità mediche, Università di Genova, Genova, Italy.
  • Cavo M; Section of Hematology, Department of Medicine, University of Verona, Verona, Italy.
  • Andriani A; Division of Hematology, University of Ferrara, Ferrara, Italy.
  • De Stefano V; Unit of Hematology and Clinical Immunology, University of Padova, Padova, Italy.
  • Palumbo GA; Hematology Unit, Ospedale Belcolle, Viterbo, Italy.
  • Breccia M; Hematology, S.Eugenio Hospital, Tor Vergata University, ASL Roma2, Rome, Italy.
Blood Cancer J ; 13(1): 65, 2023 05 03.
Article in English | MEDLINE | ID: covidwho-2317949
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Myeloproliferative Disorders Type of study: Prognostic study Limits: Humans Language: English Journal: Blood Cancer J Year: 2023 Document Type: Article Affiliation country: S41408-023-00834-6

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Myeloproliferative Disorders Type of study: Prognostic study Limits: Humans Language: English Journal: Blood Cancer J Year: 2023 Document Type: Article Affiliation country: S41408-023-00834-6